These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1826840)
1. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840 [TBL] [Abstract][Full Text] [Related]
2. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene. Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969 [TBL] [Abstract][Full Text] [Related]
3. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model. Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168 [TBL] [Abstract][Full Text] [Related]
5. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent. Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515 [TBL] [Abstract][Full Text] [Related]
6. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1. Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568 [TBL] [Abstract][Full Text] [Related]
8. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Kazmi SM; Plante RK; Visconti V; Lau CY Cancer Res; 1996 Mar; 56(5):1056-62. PubMed ID: 8640761 [TBL] [Abstract][Full Text] [Related]
9. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Simeone AM; Broemeling LD; Rosenblum J; Tari AM Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic evaluation of glucarate and N-(4-hydroxyphenyl)retinamide alone and in combination in the rat mammary tumor model. Abou-Issa H; Webb TE; Minton JP; Moeschberger M J Natl Cancer Inst; 1989 Dec; 81(23):1820-3. PubMed ID: 2531231 [TBL] [Abstract][Full Text] [Related]
11. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy? Ohlmann CH; Jung C; Jaques G Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800 [TBL] [Abstract][Full Text] [Related]
12. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis. Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467 [TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Delia D; Aiello A; Lombardi L; Pelicci PG; Grignani F; Grignani F; Formelli F; Menard S; Costa A; Veronesi U Cancer Res; 1993 Dec; 53(24):6036-41. PubMed ID: 8261419 [TBL] [Abstract][Full Text] [Related]
14. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Favoni RE; de Cupis A; Bruno S; Yee D; Ferrera A; Pirani P; Costa A; Decensi A Br J Cancer; 1998 Jun; 77(12):2138-47. PubMed ID: 9649125 [TBL] [Abstract][Full Text] [Related]
15. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth. Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125 [TBL] [Abstract][Full Text] [Related]
16. Effects of retinoid beta-glucuronides and N-retinoyl amines on the differentiation of HL-60 cells in vitro. Gallup JM; Barua AB; Furr HC; Olson JA Proc Soc Exp Biol Med; 1987 Dec; 186(3):269-74. PubMed ID: 2962197 [TBL] [Abstract][Full Text] [Related]
17. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536 [TBL] [Abstract][Full Text] [Related]
18. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. Hultin TA; Filla MS; McCormick DL Drug Metab Dispos; 1990; 18(2):175-9. PubMed ID: 1971569 [TBL] [Abstract][Full Text] [Related]
19. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents. Swanson BN; Newton DL; Roller PP; Sporn MB J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750 [TBL] [Abstract][Full Text] [Related]
20. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]